c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients
Open Access
- 11 December 2000
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 95 (4) , 266-270
- https://doi.org/10.1002/1097-0215(20010720)95:4<266::aid-ijc1045>3.0.co;2-e
Abstract
We investigated the effect of hepatocyte‐derived extracellular matrix (ECM) on the expression of erb‐B2 and erb‐B3 in colon cancer cell lines, as well as the role of erb‐B2 and erb‐B3 in colon cancer cell proliferation. Colon cancer cell lines plated on hepatocyte‐derived ECM had increased protein levels of both erb‐B2 and erb‐B3. The addition of soluble recombinant proteoglycan syndecan‐4 also resulted in higher expression of erb‐B2 and erb‐B3. We prepared hepatocyte‐derived ECM from 1 to 7 days' cultures of hepatocytes, which contained different amounts of sulfated glycosaminoglycans. There was a direct correlation between the amounts of sulfated glycosaminoglycans in the ECM and the levels of erb‐B2 and erb‐B3 in the colon cell line KM12. The stimulatory effect of hepatocyte‐derived ECM was abolished when the colon cancer cells were cultured in the presence of antibodies to erb‐B2. These studies show that hepatocyte‐derived ECM and the heparan sulfate proteoglycans present in it are responsible for inducing erb‐B2 and erb‐B3 in colon cancer cells. The growth stimulatory effect of extracellular matrix is mediated, at least in part, by increased expression of erb‐B2 and erb‐B3.Keywords
This publication has 16 references indexed in Scilit:
- Assessment of Methods for Tissue-Based Detection of the HER-2/neu Alteration in Human Breast Cancer: A Direct Comparison of Fluorescence In Situ Hybridization and ImmunohistochemistryJournal of Clinical Oncology, 2000
- The Molecular and Cellular Biology of HER2/neu Gene Amplification/Overexpression and the Clinical Development of Herceptin (Trastuzumab) Therapy for Breast CancerPublished by Springer Nature ,2000
- c-myc, p53 andbcl-2, apoptosis-related genes in infiltrating breast carcinomas: Evidence of a link between bcl-2 protein over-expression and a lower risk of metastasis and death in operable patientsInternational Journal of Cancer, 1999
- Her-2/neu as a Predictive Marker of Response to Breast Cancer TherapyBreast Cancer Research and Treatment, 1998
- Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers.Journal of Clinical Oncology, 1998
- Association of c‐erbB2‐gene amplification with poor prognosis in non‐inflammatory breast carcinomas but not in carcinomas of the inflammatory typeInternational Journal of Cancer, 1994
- Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion.Proceedings of the National Academy of Sciences, 1992
- 4. The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast cancerInternational Journal of Cancer, 1990
- Structure and expression of c‐erbB‐2 and EGF receptor genes in inflammatory and non‐inflammatory breast cancer: Prognostic significanceInternational Journal of Cancer, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987